The purpose of this study is to determine whether nicorandil reduce cardiac infarct size in patient with ST-segment elevation acute myocardial infarction.
Study objective : To investiage whether nicorandil treatment reduce infarct size measured by cardiac MRI at 6 months after primary PCI Allocation : 1. Nicorandil arm : Recieve nicorandil 4 mg i.v. before undergoing PCI, additionall 2mg i.c. just before 1st ballooning, additionall 2mg i.c. just before stenting, After successful PCI, 10 mg/day (or 5 mg/day) p.o. for 6 months. 2. Control arm : Recieve standard treatment including PCI, but avoid nicoranil and adenosine. Follow-up and Measurement : Cardiac MRI scans are scheduled at 5 days and 6 months after primary PCI. Clinically followed upto 6 months after parimary PCI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
86
4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
Pusan National University Hospital
Pusan, South Korea
RECRUITINGInfarct size as measured by cardiac MRI
Time frame: Six months after primary PCI
LVEF(%) as measured by cardiac MRI
Time frame: Five days and 6 months after primary PCI
MVO as measured by cardiac MRI
Time frame: Five days after primary PCI
ST-segment resolution
Time frame: One hour after primary PCI
MACE (Death, Spontaneous MI, Stroke)
Time frame: up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.